000278348 001__ 278348
000278348 005__ 20240229155030.0
000278348 0247_ $$2doi$$a10.1016/j.ejca.2023.113241
000278348 0247_ $$2pmid$$apmid:37549530
000278348 0247_ $$2ISSN$$a0014-2964
000278348 0247_ $$2ISSN$$a0959-8049
000278348 0247_ $$2ISSN$$a1879-0852
000278348 0247_ $$2ISSN$$a(1990)
000278348 0247_ $$2ISSN$$a1879-2995
000278348 0247_ $$2ISSN$$a(1965)
000278348 0247_ $$2altmetric$$aaltmetric:151706956
000278348 037__ $$aDKFZ-2023-01605
000278348 041__ $$aEnglish
000278348 082__ $$a610
000278348 1001_ $$0P:(DE-He78)1d6f6305a65e2f7de2c7fbffbae83780$$aSha, Sha$$b0$$eFirst author$$udkfz
000278348 245__ $$aAssociations of 25-hydroxyvitamin D status and vitamin D supplementation use with mortality due to 18 frequent cancer types in the UK Biobank cohort.
000278348 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2023
000278348 3367_ $$2DRIVER$$aarticle
000278348 3367_ $$2DataCite$$aOutput Types/Journal article
000278348 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1691502021_20940
000278348 3367_ $$2BibTeX$$aARTICLE
000278348 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000278348 3367_ $$00$$2EndNote$$aJournal Article
000278348 500__ $$a#EA:C070#LA:C070#
000278348 520__ $$aAlthough the associations of serum 25-hydroxyvitamin D (25(OH)D) levels and vitamin D supplementation with total cancer mortality are well-known, evidence regarding the association of 25(OH)D and cancer site-specific mortality is predominantly limited to common cancer types, and most studies on vitamin D supplementation use have limitations on sample size and the adjustment of important confounding factors.We used cause-specific Cox regression models adjusted for 48 covariates to assess the associations of vitamin D deficiency, insufficiency, and vitamin D supplementation use with mortality from any cancer and 18 specific cancers in 411,436 United Kingdom Biobank participants, aged 40-69 years.The majority of the study population had either vitamin D deficiency (21.1%) or insufficiency (34.4%). Furthermore, 4.1% and 20.3% of the participants regularly took vitamin D or multivitamin supplements, respectively. During a median follow-up of 12.7 years, vitamin D deficiency was associated with significantly increased mortality from total cancer and four specific cancers: stomach (hazard ratio, 95% confidence interval: 1.42, 1.05-1.92), colorectal (1.27, 1.07-1.50), lung (1.24, 1.10-1.40), and prostate (1.36, 1.06-1.75). Vitamin D insufficiency was associated with increased colorectal (1.14, 1.00-1.30) and lung cancer mortality (1.19, 1.08-1.32). Compared to non-users, vitamin D use was associated with lower lung cancer (0.75, 0.60-0.95) and total cancer mortality. Multivitamin use was associated with lower mortality from melanoma (0.64, 0.43-0.97).Vitamin D deficiency and insufficiency were associated with increased mortality from multiple common cancers. The potential to reduce cancer mortality by vitamin D supplementation in populations with low 25(OH)D levels should be further explored.
000278348 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000278348 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000278348 650_7 $$2Other$$aCancer site-specific mortality
000278348 650_7 $$2Other$$aReal-world evidence
000278348 650_7 $$2Other$$aSerum 25-hydroxyvitamin D levels
000278348 650_7 $$2Other$$aVitamin D supplement use
000278348 7001_ $$0P:(DE-He78)ad44271ecf6b1eec3e0d0089c66dfdbe$$aChen, Li-Ju$$b1$$udkfz
000278348 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b2$$udkfz
000278348 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b3$$eLast author$$udkfz
000278348 773__ $$0PERI:(DE-600)1468190-0$$a10.1016/j.ejca.2023.113241$$gVol. 191, p. 113241 -$$p113241$$tEuropean journal of cancer$$v191$$x0014-2964$$y2023
000278348 909CO $$ooai:inrepo02.dkfz.de:278348$$pVDB
000278348 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1d6f6305a65e2f7de2c7fbffbae83780$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000278348 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ad44271ecf6b1eec3e0d0089c66dfdbe$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000278348 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000278348 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000278348 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000278348 9141_ $$y2023
000278348 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-30
000278348 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-30
000278348 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-30
000278348 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000278348 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000278348 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000278348 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000278348 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000278348 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000278348 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000278348 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-21
000278348 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J CANCER : 2022$$d2023-10-21
000278348 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000278348 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000278348 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J CANCER : 2022$$d2023-10-21
000278348 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000278348 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000278348 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000278348 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000278348 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000278348 980__ $$ajournal
000278348 980__ $$aVDB
000278348 980__ $$aI:(DE-He78)C070-20160331
000278348 980__ $$aI:(DE-He78)C120-20160331
000278348 980__ $$aI:(DE-He78)HD01-20160331
000278348 980__ $$aUNRESTRICTED